Fate Therapeutics Inc
Research Fate Therapeutics Inc (FATE) on Bullrun: market cap USD 297.57M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFATE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 297.57M
- Financial periodQ1 2026
- RevenueUSD 1.30M
- Net income-USD 31.21M
- Free cash flow-USD 31.06M
Valuation Snapshot
latest market cap is USD 297.57M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.65M | -USD 136.32M | -USD 112.04M | n/a | -1.15 | USD 46.63M | USD 77.85M | USD 207.18M |
| FY2024 | USD 13.63M | -USD 186.26M | -USD 123.60M | n/a | -1.64 | USD 36.06M | USD 85.27M | USD 318.73M |
| FY2023 | USD 63.53M | -USD 160.93M | -USD 138.42M | n/a | -1.64 | USD 41.87M | USD 103.54M | USD 368.42M |
| FY2022 | USD 96.30M | -USD 281.72M | -USD 283.77M | n/a | -2.91 | USD 61.33M | USD 112.30M | USD 483.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 297.57M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 113.05M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 187.98M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 368.77M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 980.45M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.60B | n/a | n/a | n/a |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fate Therapeutics Inc's market cap?
Fate Therapeutics Inc's market capitalization is USD 297.57M.
What does Fate Therapeutics Inc do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors.